April 20, 2017

DelMar’s New Chemotherapeutic VAL-083 Shows Promise in TKI-resistant NSCLC

News

DelMar‘s small molecule chemotherapeutic VAL-083 may be a valuable treatment approach for non-small cell lung cancer (NSCLC) patients who are resistant to tyrosine kinase therapy, according to preclinical data presented ... Read more

September 5, 2014September 5, 2014

DelMar Pharmaceuticals’ Lung Cancer Drug VAL-083 Gets Notice of Allowance For Second U.S. Patent

Lung cancer News, News

DelMar Pharmaceuticals, a biotechnology company developing proven cancer therapies in new orphan drug indications, has announced that the United States Patent and Trademark Office (USPTO) issued a notice of allowance ... Read more